par Rahal, James J.J.;Gatenby, Paul P.A.;Larocco, Anthony;Oldfield, Edward E.C.;Lucet, Jean Christophe;Bedos, Jean Pierre;Wolff, Michel;Regnier, Bernard;Bozzette, Samuel S.A.;Masur, Henry;Meier, Paul;Clumeck, Nathan 
;McCutchan, John Allen;Feinberg, Judith;Hermans, Philippe ;El-Sadr, Wafaa;Milder, James;Capps, Linnea;Sivapalan, Vel;Ellison, Richard ;Baumgart, Karl K.W.
Référence The New England journal of medicine, 324, 23, page (1666-1669)
Publication Publié, 1991-06
;McCutchan, John Allen;Feinberg, Judith;Hermans, Philippe ;El-Sadr, Wafaa;Milder, James;Capps, Linnea;Sivapalan, Vel;Ellison, Richard ;Baumgart, Karl K.W.Référence The New England journal of medicine, 324, 23, page (1666-1669)
Publication Publié, 1991-06
Lettre à l'éditeur
| Résumé : | To the Editor: The National Institutes of Health (NIH)—University of California Expert Panel has concluded (Nov. 22 issue)1 that early adjunctive corticosteroid therapy benefits patients with moderate-to-severe Pneumocystis carinii pneumonia. The consensus panel has recommended the regimen used by the California Collaborative Treatment Group, which provides an initial daily dose of 80 mg of oral prednisone, tapered to 20 mg during a 21-day course.2 An alternative approach, not studied in any of the recent trials, was used by my colleagues and me in one of the early reports of successful adjunctive corticosteroid therapy for P. carinii pneumonia.3 Three patients had. © 1991, Massachusetts Medical Society. All rights reserved. |
